{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,4]],"date-time":"2026-05-04T07:27:22Z","timestamp":1777879642396,"version":"3.51.4"},"reference-count":18,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,3,24]],"date-time":"2026-03-24T00:00:00Z","timestamp":1774310400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2026,5,1]],"date-time":"2026-05-01T00:00:00Z","timestamp":1777593600000},"content-version":"vor","delay-in-days":38,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Neurol"],"DOI":"10.1186\/s12883-026-04841-5","type":"journal-article","created":{"date-parts":[[2026,3,24]],"date-time":"2026-03-24T00:13:37Z","timestamp":1774311217000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Successful treatment of Anti-NF155 antibody positive autoimmune nodopathy with telitacicept: a case report"],"prefix":"10.1186","volume":"26","author":[{"given":"Zhuqing","family":"Luan","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Minghui","family":"Du","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Zhigang","family":"Liang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Fuxia","family":"Song","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2026,3,24]]},"reference":[{"issue":"5","key":"4841_CR1","doi-asserted-by":"publisher","first-page":"579","DOI":"10.1097\/WCO.0000000000001107","volume":"35","author":"L Mart\u00edn-Aguilar","year":"2022","unstructured":"Mart\u00edn-Aguilar L, Lleix\u00e0 C, Pascual-Go\u00f1i E. Autoimmune nodopathies, an emerging diagnostic category. Curr Opin Neurol. 2022;35(5):579\u201385. https:\/\/doi.org\/10.1097\/WCO.0000000000001107.","journal-title":"Curr Opin Neurol"},{"issue":"3","key":"4841_CR2","doi-asserted-by":"publisher","first-page":"242","DOI":"10.1111\/jns.12455","volume":"26","author":"PYK Van den Bergh","year":"2021","unstructured":"Van den Bergh PYK, van Doorn PA, Hadden RDM, Avau B, Vankrunkelsven P, Allen JA, et al. European Academy of Neurology\/Peripheral Nerve Society guideline on diagnosis and treatment of chronic inflammatory demyelinating polyradiculoneuropathy: report of a joint task force-second revision. J Peripher Nerv Syst. 2021;26(3):242\u201368. https:\/\/doi.org\/10.1111\/jns.12455.","journal-title":"J Peripher Nerv Syst"},{"issue":"5","key":"4841_CR3","doi-asserted-by":"publisher","first-page":"e817","DOI":"10.1212\/NXI.0000000000000817","volume":"7","author":"L Appeltshauser","year":"2020","unstructured":"Appeltshauser L, Brunder AM, Heinius A, K\u00f6rtv\u00e9lyessy P, Wandinger KP, Junker R, et al. Antiparanodal antibodies and IgG subclasses in acute autoimmune neuropathy. Neurol Neuroimmunol Neuroinflamm. 2020;7(5):e817. https:\/\/doi.org\/10.1212\/NXI.0000000000000817. Published 2020 Jul 24.","journal-title":"Neurol Neuroimmunol Neuroinflamm"},{"issue":"6","key":"4841_CR4","doi-asserted-by":"publisher","first-page":"666","DOI":"10.1080\/08923973.2021.1973493","volume":"43","author":"F Shi","year":"2021","unstructured":"Shi F, Xue R, Zhou X, Shen P, Wang S, Yang Y. Telitacicept as a BLyS\/APRIL dual inhibitor for autoimmune disease. Immunopharmacol Immunotoxicol. 2021;43(6):666\u201373. https:\/\/doi.org\/10.1080\/08923973.2021.1973493.","journal-title":"Immunopharmacol Immunotoxicol"},{"key":"4841_CR5","doi-asserted-by":"publisher","first-page":"103291","DOI":"10.1016\/j.jaut.2024.103291","volume":"148","author":"L Zeng","year":"2024","unstructured":"Zeng L, Yang K, Wu Y, Yu G, Yan Y, Hao M, et al. Telitacicept: a novel horizon in targeting autoimmunity and rheumatic diseases. J Autoimmun. 2024;148:103291. https:\/\/doi.org\/10.1016\/j.jaut.2024.103291.","journal-title":"J Autoimmun"},{"key":"4841_CR6","doi-asserted-by":"publisher","first-page":"986018","DOI":"10.3389\/fimmu.2022.986018","volume":"13","author":"L Liu","year":"2022","unstructured":"Liu L, Chen J, Zhang Y, Wu J, Hu J, Lin Z. Case report: Immunoadsorption therapy for anti-caspr1 antibody-associated nodopathy. Front Immunol. 2022;13:986018. https:\/\/doi.org\/10.3389\/fimmu.2022.986018. Published 2022 Sep 21.","journal-title":"Front Immunol"},{"key":"4841_CR7","doi-asserted-by":"publisher","unstructured":"Ren Y, Chen S, Yang H. Case report: telitacicept in treating a patient with NF155\u2009+\u2009autoimmune nodopathy: a successful attempt to manage recurrent elevated sero-anti-NF155 antibodies. Front Immunol. 2023;14:1279808. https:\/\/doi.org\/10.3389\/fimmu.2023.1279808.\u00a0Published 30\u00a0Oct 2023.","DOI":"10.3389\/fimmu.2023.1279808"},{"issue":"5","key":"4841_CR8","doi-asserted-by":"publisher","first-page":"e200014","DOI":"10.1212\/NXI.0000000000200014","volume":"9","author":"A Jentzer","year":"2022","unstructured":"Jentzer A, Attal A, Rou\u00e9 C, Raymond J, Lleix\u00e0 C, Illa I, et al. IgG4 valency modulates the pathogenicity of anti-neurofascin-155 IgG4 in autoimmune nodopathy. Neurol Neuroimmunol Neuroinflamm. 2022;9(5):e200014. https:\/\/doi.org\/10.1212\/NXI.0000000000200014. Published 2022 Aug 10.","journal-title":"Neurol Neuroimmunol Neuroinflamm"},{"issue":"5","key":"4841_CR9","doi-asserted-by":"publisher","first-page":"534","DOI":"10.11477\/mf.1416202640","volume":"76","author":"H Ogata","year":"2024","unstructured":"Ogata H. Brain Nerve. 2024;76(5):534\u20139. https:\/\/doi.org\/10.11477\/mf.1416202640.","journal-title":"Brain Nerve"},{"key":"4841_CR10","doi-asserted-by":"publisher","unstructured":"Kira JI. Anti-neurofascin 155 antibody-positive chronic inflammatory demyelinating polyneuropathy\/combined central and peripheral demyelination: strategies for diagnosis and treatment based on the disease mechanism. Front Neurol. 2021;12:665136. https:\/\/doi.org\/10.3389\/fneur.2021.665136.\u00a0Published 10 Jun 2021.","DOI":"10.3389\/fneur.2021.665136"},{"issue":"1","key":"4841_CR11","doi-asserted-by":"publisher","first-page":"e1129","DOI":"10.1212\/NXI.0000000000001129","volume":"9","author":"Clinical and Laboratory Features in Anti-NF155 Autoimmune Nodopathy","year":"2021","unstructured":"Clinical and Laboratory Features in Anti-NF155 Autoimmune Nodopathy. Neurol Neuroimmunol Neuroinflamm. 2021;9(1):e1129. https:\/\/doi.org\/10.1212\/NXI.0000000000001129. Published 2021 Dec 20.","journal-title":"Neurol Neuroimmunol Neuroinflamm"},{"key":"4841_CR12","doi-asserted-by":"publisher","first-page":"1121705","DOI":"10.3389\/fimmu.2023.1121705","volume":"14","author":"Y Bai","year":"2023","unstructured":"Bai Y, Li W, Yan C, Hou Y, Wang Q. Anti-rituximab antibodies in patients with refractory autoimmune nodopathy with anti-neurofascin-155 antibody. Front Immunol. 2023;14:1121705. https:\/\/doi.org\/10.3389\/fimmu.2023.1121705. Published 2023 Mar 28.","journal-title":"Front Immunol"},{"issue":"1","key":"4841_CR13","doi-asserted-by":"publisher","first-page":"183","DOI":"10.55563\/clinexprheumatol\/ftira8","volume":"40","author":"I Oomen","year":"2022","unstructured":"Oomen I, Nassar-Sheikh Rashid A, Bouts AHM, Gouw SC, Kuijpers TW, Rispens T, et al. Anti-rituximab antibodies affect pharmacokinetics and pharmacodynamics of rituximab in children with immune-mediated diseases. Clin Exp Rheumatol. 2022;40(1):183\u201390. https:\/\/doi.org\/10.55563\/clinexprheumatol\/ftira8.","journal-title":"Clin Exp Rheumatol"},{"key":"4841_CR14","doi-asserted-by":"publisher","first-page":"3069","DOI":"10.3389\/fimmu.2019.03069","volume":"10","author":"S Boyer-Suavet","year":"2020","unstructured":"Boyer-Suavet S, Andreani M, Lateb M, et al. Neutralizing anti-rituximab antibodies and relapse in membranous nephropathy treated with rituximab. Front Immunol. 2020;10:3069. https:\/\/doi.org\/10.3389\/fimmu.2019.03069. Published 2020 Jan 13.","journal-title":"Front Immunol"},{"issue":"8","key":"4841_CR15","doi-asserted-by":"publisher","first-page":"e16322","DOI":"10.1111\/ene.16322","volume":"31","author":"J Yin","year":"2024","unstructured":"Yin J, Zhao M, Xu X, Zhang M, Xu Z, Li Z, et al. A multicenter, randomized, open-label, phase 2 clinical study of telitacicept in adult patients with generalized myasthenia gravis. Eur J Neurol. 2024;31(8):e16322. https:\/\/doi.org\/10.1111\/ene.16322.","journal-title":"Eur J Neurol"},{"issue":"14","key":"4841_CR16","doi-asserted-by":"publisher","first-page":"1671","DOI":"10.1007\/s40265-021-01591-1","volume":"81","author":"S Dhillon","year":"2021","unstructured":"Dhillon S. Telitacicept: first approval drugs. 2021;81(14):1671\u20135. https:\/\/doi.org\/10.1007\/s40265-021-01591-1.","journal-title":"Telitacicept: first approval drugs"},{"issue":"2","key":"4841_CR17","doi-asserted-by":"publisher","first-page":"266","DOI":"10.1002\/art.40360","volume":"70","author":"JT Merrill","year":"2018","unstructured":"Merrill JT, Wallace DJ, Wax S, Kao A, Fraser PA, Chang P, et al. Efficacy and safety of atacicept in patients with systemic lupus erythematosus: results of a twenty-four-week, multicenter, randomized, double-blind, placebo-controlled, parallel-arm, phase IIb study. Arthritis Rheumatol. 2018;70(2):266\u201376. https:\/\/doi.org\/10.1002\/art.40360.","journal-title":"Arthritis Rheumatol"},{"issue":"3","key":"4841_CR18","doi-asserted-by":"publisher","first-page":"322","DOI":"10.1016\/j.clim.2012.11.010","volume":"148","author":"A La Cava","year":"2013","unstructured":"La Cava A. Targeting the BLyS-APRIL signaling pathway in SLE. Clin Immunol. 2013;148(3):322\u20137. https:\/\/doi.org\/10.1016\/j.clim.2012.11.010.","journal-title":"Clin Immunol"}],"container-title":["BMC Neurology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12883-026-04841-5","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12883-026-04841-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12883-026-04841-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,4,30]],"date-time":"2026-04-30T23:49:36Z","timestamp":1777592976000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1186\/s12883-026-04841-5"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,3,24]]},"references-count":18,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["4841"],"URL":"https:\/\/doi.org\/10.1186\/s12883-026-04841-5","relation":{},"ISSN":["1471-2377"],"issn-type":[{"value":"1471-2377","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,3,24]]},"assertion":[{"value":"6 January 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"17 March 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"24 March 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"YantaiYuhuangding Hospital Affiliated to Qingdao University. The studies were conducted in accordance with the local legislation and institutional requirements. The participants provided their written informed consent to participate in this study.Written informed consent was obtained from the individual(s) for the publication of any potentially identifiable images or data included in this article. Written informed consent was obtained from the patient for publication of this case report.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to partcipate"}},{"value":"Written informed consent was obtained from the patient for publication of this case report, including any accompanying images. A copy of the consent form is available for review by the Editor of this journal.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"292"}}